ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VER Vernalis

6.17
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.17 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Vernalis Share Discussion Threads

Showing 3101 to 3124 of 3850 messages
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older
DateSubjectAuthorDiscuss
08/9/2015
07:27
The lack of interest in this share is v surprising. I've just topped up with this good news.
investordave
08/9/2015
06:52
Bang on time for the 2015 cold and cough season. Just the tonic we need!
fhmktg
14/8/2015
10:02
Well done if you bought. If you sold, I think you may regret it in the mid to long term.
investordave
13/8/2015
19:43
That's why I didn't say. It still doesn't show today - I guess my broker goes through a clearing house.
gbb483
13/8/2015
09:07
gbb483 - Buy or sell if you don't mind me asking?
investordave
12/8/2015
17:45
Strange, I traded these today but the trade hasn't appeared on the list.
gbb483
11/8/2015
16:43
Untold joy!!!
At last, patience rewarded!
dum spiro spero.

fhmktg
11/8/2015
15:31
Vernalis (VER +
), a UK biotech business focused on cough and cold treatments, was one of the fund's top performers. Shares in the company have jumped nearly 60% after the approval of Tuzitra, its first cough-cold product, in April. 'Investors continue to significantly undervalue the potential of Vernalis' cough cold franchise,' said Woodford.

twodegrees
11/8/2015
15:29
woodhouse yippee
twodegrees
11/8/2015
14:58
Vernalis is preparing for commercial launch of Tuzistra XR, its extended-release, codeine-based cough cold treatment following FDA approval in April. The product has greater commercial potential than previously anticipated with an addressable market of up to £1.8bn and is the only approved codeine-based, long-release liquid treatment. We forecast maiden cough cold sales in FY16 leading to profitability in FY18. We increase our valuation from £323m to £406m.
Year end
Revenue (£m)
PBT* (£m)
EPS* (p)
DPS (p)
P/E (x)
Yield (%)
12/12
14.6
(2.7)
(0.8)
0.0
N/A
N/A
12/13
14.1
(4.7)
(0.8)
0.0
N/A
N/A
06/15e
18.9
(13.1)
(1.8)
0.0
N/A
N/A
06/16e
17.7
(21.3)
(4.2)
0.0
N/A
N/A
Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments and FX gains/losses on cash holdings.
FDA approval of Tuzistra XR
Tuzistra XR, a 12-hourly dosed or extended-release (ER) liquid narcotic cough cold treatment was FDA approved on 30 April. Tuzistra XR is indicated for the relief of cough and symptoms associated with respiratory tract allergies and common cold. Its active ingredients, disclosed at the time of the FDA approval, are codeine, a cough suppressant and chlorpheniramine, an antihistamine. Its primary market, the codeine plus antihistamines segment, has an estimated value of £510m at current net brand pricing, although Tuzistra XR has potential in other market segments.
Commercial potential in expanded markets
Tuzistra XR has additional potential among all codeine cough cold prescribers, a c $1.2bn market, including codeine plus expectorant products. Furthermore, DEA reclassification in 2014 of hydrocodone-based cough cold products from Schedule III into the more restrictive Schedule II could drive Tuzistra XR sales into the $550m hydrocodone segment. Vernalis has a pipeline of four ER products, providing further commercial potential in the c $3.3bn prescription cough cold market.
Maiden cough cold revenues forecast in FY16
We have increased our FY15 sales estimate from £18.4m to £18.9m, adding in a £0.5m research milestone payment. We have lowered our FY16 sales estimate from £18.3 to £17.7m, with greater caution on cough cold sales in launch year, but we increase our peak sales estimate for Tuzistra XR to $240m from $120m, c 13% of the addressable cough cold market. Our end-2015 net cash estimate is £54.6m, which we forecast is sufficient to fund Vernalis through to profitability in 2018.

twodegrees
11/8/2015
14:57
Equity Research (VER)





edison investment research

Vernalis plc

Vernalis - Tuzistra Xr; Us Commercial Potential Unveiled

17/06/2015

twodegrees
11/8/2015
14:55
10,000 at 81.86 and it is an ordinary trade...as you say investor dave...something is brewing. and I am glad I did not bail out.
twodegrees
11/8/2015
14:53
a few weeks back some decent large buys happened, I think woodhouse, if I remember has taken a position and other news suggested that the value of shares should be more than £1.

Apologies if I have given the wrong information re name above...but certainly it was done

twodegrees
11/8/2015
14:16
The question is why is the share price ticking up. Clearly something is going on that we mere mortals don't know about.
investordave
11/8/2015
13:57
December 2009 was £1.05 , I think it will surpass that price this time
twodegrees
11/8/2015
13:56
I have just got back all my loses for the last 5 years at this price...
twodegrees
11/8/2015
13:07
Something brewing folks?
investordave
06/8/2015
15:15
so no RNS but still keeps ticking up nicely, I had a £6k loss at one point and quickly making that up.
twodegrees
05/8/2015
15:47
Even if it was a 'sell' the interesting question is Who? was the buyer... If it was a buy then who was the seller ? Perhaps an RNS one way or the other might be on its way.
rosejs2
05/8/2015
15:38
Was that a big sell or buy after hours today? It looks like a sell given the closing price although I hope not.
investordave
31/7/2015
06:47
Two degrees. Long may it continue.
investordave
24/7/2015
15:31
this keeps moving higher, nice and steady
twodegrees
17/6/2015
04:41
Vernalis plc (LON:VER)‘s stock had its “buy” rating reiterated by equities research analysts at Stifel Nicolaus in a research note issued to investors on Thursday. They currently have a GBX 103 ($1.57) target price on the stock. Stifel Nicolaus’ target price points to a potential upside of 41.58% from the company’s current price.

Vernalis plc (LON:VER) opened at 72.5500 on Thursday. Vernalis plc has a 52 week low of GBX 30.7500 and a 52 week high of GBX 74.5750. The stock has a 50-day moving average of GBX 62.20 and a 200-day moving average of GBX 51.91. The company’s market cap is £320.90 million.

Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating and set a GBX 92 ($1.40) price target on shares of Vernalis plc in a research note on Thursday. Separately, analysts at N+1 Singer reiterated a “buy” rating and set a GBX 87 ($1.33) price target on shares of Vernalis plc in a research note on Friday, May 1st.

Vernalis plc is a United Kingdom-based research and development-stage pharmaceutical company. Vernalis has one marketed product and a portfolio of development and drug discovery programmes. Vernalis has nine active collaborations, four covering programmes in pre-clinical through to Phase II development and four active drug discovery collaborations.

twodegrees
12/6/2015
15:42
It's that man again- Mr W now over 21%!
Statement of confidence if ever I heard one!
Onwards and upwards!

fhmktg
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older

Your Recent History

Delayed Upgrade Clock